Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective To examine acute (single-bout) and training effects of high-intensity interval training (HIIT) vs standard exercise therapy (moderate continuous training [MCT]) on plasma neurofilament light chain (pNfL) and kynurenine (KYN) pathway of tryptophan degradation metabolites in persons with multiple sclerosis (pwMS).
Methods Sixty-nine pwMS (Expanded Disability Status Scale score 3.0–6.0) were randomly assigned to a HIIT or an MCT group. Changes in pNfL and KYN pathway metabolites measured in blood plasma were assessed before, after, and 3 hours after the first training session as well as after the 3-week training intervention.
Results Acute exercise reduced pNfL and increased the KYN pathway flux toward the neuroprotective kynurenic acid (KA). Changes in pNfL correlated positively with changes in KA and negatively with the quinolinic acid-to-KA ratio. HIIT consistently led to greater effects than MCT. Following the 3-week training intervention, the KYN pathway was activated in HIIT compared with MCT.
Conclusion Future studies and clinical assessments of pNfL should consider acute exercise as confounding factor for measurement reliability. Moreover, exercise-induced KYN pathway rerouting might mediate neuroprotection, potentially underlying the benefits in rehabilitation for pwMS.
Classification of Evidence This study provides Class II evidence that acute HIIT diminishes pNfL and increases KA levels, and 3 weeks of HIIT activate the KYN pathway in pwMS.
Trial Registration Information Clinical trial registration number: NCT03652519.
Glossary
- CV=
- coefficient of variation;
- EDSS=
- Expanded Disability Status Scale;
- HIIT=
- high-intensity interval training;
- HPLC-MS/MS=
- high-performance liquid chromatography–tandem mass spectrometry;
- IL-6=
- interleukin-6;
- KA=
- kynurenic acid;
- KYN=
- kynurenine;
- MCT=
- moderate continuous training;
- pNfL=
- plasma neurofilament light chain;
- pwMS=
- persons with multiple sclerosis;
- QA=
- quinolinic acid;
- TRP=
- tryptophan
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
↵* These authors contributed equally to this work.
↵† These authors share senior authorship.
The Article Processing Charge was funded by the authors.
- Received October 21, 2020.
- Accepted in final form January 21, 2021.
- Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MSThanos Tsaktanis, Tobias Beyer, Lucy Nirschl et al.Neurology: Neuroimmunology & Neuroinflammation, December 24, 2020 -
Article
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSVeit Rothhammer, Davis M. Borucki, Maria Isabel Garcia Sanchez et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017 -
Article
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple SclerosisAna Cirac, Thanos Tsaktanis, Tobias Beyer et al.Neurology: Neuroimmunology & Neuroinflammation, July 23, 2021 -
Editorial
Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activityJoseph J. Sabatino, Jr, Scott S. Zamvil et al.Neurology: Neuroimmunology & Neuroinflammation, June 16, 2017